Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968277 | PMC |
| http://dx.doi.org/10.7555/JBR.28.20140031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies.
Appl Biochem Biotechnol
December 2024
Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, 111 Ren'ai Road, SD334F, Suzhou, 215123, Jiangsu, China.
Non-alcoholic steatohepatitis (NASH) is a potential serious disease, which almost has no available medicine for effective treatment today. Efruxifermin is a bivalent Fc-FGF21 candidate drug developed by Akero Therapeutics that has shown promising results in preclinical and clinical trials for NASH and may be approved in future. However, it is produced by Escherichia coli (E.
View Article and Find Full Text PDFEfficacy and Safety Profile of Biosimilar Polyethylene Glycol (PEG)-Asparaginase (Asviia) in Patients With Acute Leukemia: A Retrospective Study From Kashmir.
Cureus
November 2024
Medical Affairs, Zydus Lifesciences LTD, Ahmedabad, IND.
Background: Biosimilar pegylated L-asparaginase offers a promising alternative to the innovator molecule for treating acute lymphoblastic leukemia (ALL) in Indian children. It addresses challenges associated with drug availability and cost while providing similar therapeutic advantages. This biosimilar ensures wider access to essential treatment in resource-limited settings such as India.
View Article and Find Full Text PDFAn exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.
Diabetes Obes Metab
December 2024
College of Medicine, California Northstate University College of Medicine, Elk Grove, California, USA.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are at the forefront of treating the global health crisis of diabetes mellitus (DM) and obesity. However, the demand for GLP-1 RAs has far outstripped its supply and comes with a high monthly cost. Thus, the development of GLP-1 RA biosimilars can potentially address these barriers by providing greater access to medications that provide clinical outcomes similar to those of the reference products.
View Article and Find Full Text PDFShifting paradigms in retinopathy of prematurity treatment: The promise and challenges of biosimilars.
Clin Exp Ophthalmol
December 2024
Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital NHS Trust, London, UK.
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis.
BMC Gastroenterol
November 2024
Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Background: Since 2015, an infliximab biosimilar, CT-P13, has been approved for commercial use in many countries, easing the economic burden borne by society and patients. Many clinical trials investigating CT-P13 for the treatment of IBD have been conducted and reported that it may be a substitute for infliximab. However, the differences between the efficacy of CT-P13 and infliximab-originator require further elucidation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!